CENTERS FOR DISEASE CONTROL



MORBIDITY AND MORTALITY WEEKLY REPORT

**Current Trends** 

# Deaths from Oral Cavity and Pharyngeal Cancer – United States, 1987

In 1987, more than 9700 deaths in the United States were caused by cancers of the oral cavity and pharynx.\* Many of these deaths could have been prevented by reduction of personal risk behaviors (e.g., tobacco use and heavy alcohol consumption). This report summarizes epidemiologic data on deaths caused by oral and pharyngeal cancer in the United States in 1987.

Deaths from cancers of the oral cavity and pharynx were identified from total mentions in the multiple cause-of-death file<sup>†</sup> compiled by CDC's National Center for Health Statistics (NCHS). Denominators for 1987 rate calculations were determined from intercensal population estimates (2). Death rates were standardized to the 1970 age distribution of the U.S. population and were analyzed by age, race, sex, and state of residence.

In 1987, the national death rate for cancer of the oral cavity and pharynx was 3.6 per 100,000 persons. The death rate for males (5.6 per 100,000) was 2.8 times higher than that for females (2.0 per 100,000). The death rate for blacks (5.7 per 100,000) was 1.7 times the death rate for whites (3.4 per 100,000); the death rate for other races was 2.4 per 100,000.

Patterns of oral cavity and pharyngeal cancer mortality differed by age between blacks and whites (Figure 1). For whites, oral and pharyngeal cancer death rates steadily increased with age, peaking at ages  $\geq$ 75 years with 35.9 deaths per 100,000 males and 16.1 deaths per 100,000 females. In comparison, the death rates for blacks peaked at ages 55–64 years (35.4 per 100,000 males and 9.6 per 100,000 females), then remained at that level through ages  $\geq$ 75 years.

Oral and pharyngeal cancer death rates varied by area: they were highest in the District of Columbia (6.3 per 100,000) and lowest in South Dakota and Utah (1.4 per 100.000) (Table 1). Total deaths from oral and pharyngeal cancer for 1987 ranged from 10 deaths in Wyoming to 1053 deaths in California.

Reported by: Soft Tissue, Cranio-Facial Defects, and Pain Section, Epidemiology and Oral Disease Prevention Program, National Institute of Dental Research, National Institutes of Health.

\*International Classification of Diseases, Ninth Revision, Clinical Modification, rubrics 141–149. <sup>†</sup>A public-use tape file that contains a data record for all deaths processed by NCHS. Each data record includes multiple cause, underlying cause, and demographic data for a death (1).

July 13, 1990 / Vol. 39 / No. 27

- **457** Deaths from Oral Cavity and Pharyngeal Cancer – United States, 1987
- 460 Psittacosis at a Turkey Processing Plant — North Carolina, 1989
- 469 Clarification: Vol. 39, No. RR-7
- 470 Rabies and Rickettsial Diseases Hotline


#### Oral Cavity and Pharyngeal Cancer - Continued


Dental Disease Prevention Activity, Center for Prevention Svcs; Cancer Prevention and Control Br, Aging and Statistics Br, Div of Chronic Disease Control and Community Intervention, Center for Chronic Disease Prevention and Health Promotion, CDC.

**Editorial Note:** The survival rate for persons with cancer of the oral cavity and pharynx is among the lowest of the major cancers, with a 5-year relative survival rate of 52% (*3*). In contrast to some other cancers (e.g., breast, colorectal, and prostate cancers), the overall survival rate from oral and pharyngeal cancer has not improved during the past 16 years, and survival rates for blacks have decreased (*4*).

Factors contributing to the risk of developing oral cavity and pharyngeal cancer include increasing age, tobacco use (smoked and smokeless), and alcohol consumption (5). The combined risks from tobacco and alcohol use appear to be substantially greater than those from tobacco or alcohol alone (6). A substantial reduction in either risk factor could dramatically reduce oral and pharyngeal cancer rates. Oral cavity and pharyngeal cancer deaths ranked 16th among all cancer deaths in the United States in 1987; the increased use of tobacco among women, adolescents, and children is likely to elevate death rates for these cancers in the next several decades (7).

As with most cancers, early detection and prompt treatment are critical to improve survival. With early detection and timely treatment, public health professionals, clinicians, and other health-care providers could reduce substantially the mortality from oral cavity and pharyngeal cancer. Historically, dental health professionals have been ascribed primary responsibility for performing thorough oral, head, and neck examinations on patients. However, surveys in 1986 show that persons at highest risk for developing oral and pharyngeal cancer seek physician services four times more frequently than dental services (8). Thus, reduction of oral and pharyngeal cancer mortality could result from intervention efforts that include greater involvement and training of all health professionals in appropriate examination methods, referrals, and follow-ups for high-risk patients. These interventions could also assist in achieving





\*Per 100,000 population.

## Oral Cavity and Pharyngeal Cancer - Continued

TABLE 1. Oral cavity and pharyngeal cancer deaths and age-adjusted death rates*, by
area, sex, and race – United States, 1987

				Rate	-	
	No.			Sex	Ra	ce
Area	deaths	Total	Male	Female	White	Black
Alabama	175	3.8	6.2	2.0	3.7	4.4
Alaska	13	5.7	7.9	4.4	5.9	
Arizona	99	2.6	3.9	1.6	2.6	7.5
Arkansas	76	2.3	3.1	1.8	2.4	2.1
California	1053	3.7	5.5	2.3	3.6	5.7
Colorado	77	2.7	4.1	1.5	2.6	5.5
Connecticut	161	4.1	6.2	2.5	4.1	4.5
Delaware	29	4.0	5.3	3.1	3.4	8.5
District of Columbia	45	6.3	12.5	1.7	5.4	6.9
Florida	705	4.0	6.1	2.3	3.7	6.8
Georgia	257	4.3	7.2	2.1	3.9	5.7
Hawaii	42	3.8	5.5	2.2	6.0	÷.,
Idaho	20	2.0	2.4	1.6	2.0	t
Illinois	490	3.8	6.0	2.2	3.5	6.0
Indiana	201	3.3	5.0	1.9	3.1	6.2
lowa	105	3.0	5.0	1.4	3.0	0.2
Kansas	72	2.4	3.5	1.5	2.3	6.4
	149	2.4 3.5	5.6	1.5	3.2	8.0
Kentucky				1.9	3.2 4.0	
Louisiana	177	4.3	7.1	3.2	4.0	5.3
Maine	60	4.2	5.4			0.0
Maryland	218	4.7	8.0	2.0	3.8	8.6
Massachusetts	306	4.2	6.5	2.6	4.2	7.3
Michigan	345	3.5	5.5	1.9	3.2	5.8
Minnesota	124	2.5	4.0	1.3	2.5	
Mississippi	109	3.9	6.9	1.6	4.0	3.7
Missouri	149	2.4	3.6	1.5	2.3	3.5
Montana	34	3.9	6.9	1.4	4.0	Ť
Nebraska	55	3.1	5.1	1.5	2.9	†
Nevada	36	3.5	4.9	2.4	3.4	†
New Hampshire	45	3.9	6.0	2.3	3.9	+
New Jersey	372	4.1	7.1	1.8	3.7	7.3
New Mexico	30	2.1	3.4	1.1	1.9	+
New York	837	3.9	6.4	2.1	3.7	5.3
North Carolina	274	4.0	6.0	2.3	3.5	5.9
North Dakota	24	3.1	4.7	1.5	3.1	- · · · · · · · · · · · · · · · · · · ·
Ohio	441	3.6	5.7	2.0	3.4	5.9
Oklahoma	134	3.6	5.9	1.8	3.6	6.0
Oregon	127	3.9	5.0	3.1	3.9	0.0
Pennsylvania	534	3.5	5.8	1.8	3.2	7 2
Rhode Island	51	3.9	5.6	2.5	3.8	7.2
South Carolina	169	5.0	8.0	2.5	3.8 4.1	
South Dakota	13	1.4	1.9			7.6
Tennessee	187	3.4		1.0	1.4	
Texas	437		5.0	2.1	3.1	5.4
Utah		2.8	4.1	1.7	2.7	3.Q
Vermont	20	1.4	2.0	0.9	1.4	1 †
Virginia	18	3.1	5.2	1.3	3.2	
	232	3.9	5.9	2.4	3.6	5.6
Washington	152	3.1	4.0	2.4	3.2	5.0
West Virginia	59	2.6	3.8	1.6	2.4	†
Wisconsin	194	3.5	5.4	2.0	3.5	3.8
Wyoming	10	2.5	4.4	0.9	2.5	Ť
Total	9742	3.6	5.6	2.0	3.4	5.7

\*Per 100,000 population. <sup>†</sup>Rate does not meet standard of precision (<100,000 blacks residing in state).

### Oral Cavity and Pharyngeal Cancer - Continued

the year 2000 health objective of reducing deaths caused by cancer of the oral cavity and pharynx in men aged 45–74 years from 13.2 per 100,000 in 1987 to  $\leq$ 9.4 per 100,000<sup>§</sup> and in women aged 45–74 years from 4.7 per 100,000 in 1987 to  $\leq$ 4.0 per 100,000 (*g*).

References

- NCHS. Vital statistics mortality data, multiple cause of death detail, 1987 [machine-readable public-use data tape]. Hyattsville, Maryland: US Department of Health and Human Services, Public Health Service, CDC, 1990.
- Bureau of the Census. 1980–1990 Intercensal population estimates by race, sex, and age [machine-readable data files]. Washington, DC: US Department of Commerce, Bureau of the Census, nd.
- American Cancer Society, Cancer facts and figures 1990. Atlanta: American Cancer Society, 1990; ACS no. 5008-LE.
- National Cancer Institute. Cancer statistics review, 1973–1987. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, 1990; NIH publication no. (PHS)90-2789.
- Blot WJ, McLaughlin JK, Winn DM. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48:3282–7.
- 6. McCoy GD, Wynder EL. Etiological and preventive implications in alcohol carcinogenesis. Cancer Res 1979;39:2844–50.
- US Department of Health and Human Services. The health consequences of using smokeless tobacco: a report of the Advisory Committee to the Surgeon General. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, 1986; DHHS publication no. (NIH)86-2874.
- Bureau of the Census. Statistical abstract of the United States, 1990. 110th ed. Washington, DC: US Department of Commerce, Bureau of the Census, 1990.
- Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives [Draft]. Washington, DC: US Department of Health and Human Services, Public Health Service, 1990.

<sup>§</sup>Year 2000 goals are for underlying cause of death.

# Epidemiologic Notes and Reports

# Psittacosis at a Turkey Processing Plant – North Carolina, 1989

On October 14 and 15, 1989, a physician in North Carolina treated two poultry workers from a turkey processing plant (plant A) in North Carolina for possible psittacosis. Following notification on October 16, the Division of Epidemiology, North Carolina Department of Environment, Health, and Natural Resources, conducted a telephone survey of 12 health-care providers in the locality around plant A and identified 32 adults (aged 18–50 years) who had been evaluated for febrile respiratory or gastrointestinal illnesses during the first 2 weeks of October. These persons were considered as having suspected psittacosis, and all were employees at plant A. This report describes the investigation of this outbreak of psittacosis, which was the largest documented in North Carolina since 1956.

Persons with suspected psittacosis were identified by reviews of patient records at the plant clinic, area hospitals, area physicians' offices and clinics, and county health departments and by reviews of information from the Virology/Serology Section of the North Carolina State Laboratory for Public Health. A suspected case of psittacosis was

### Psittacosis - Continued


defined as a febrile, respiratory, or gastrointestinal illness with onset during October in an employee at plant A; a confirmed case was defined as a suspected case having at least one of the following laboratory findings: 1) isolation of *Chlamydia psittaci* from a patient specimen, 2) a fourfold rise in complement-fixation (CF) antibody to *Chlamydia* group antigen, or 3) a single *Chlamydia* CF titer of  $\geq$ 32. Acute-phase serum specimens were obtained within 14 days of illness onset; convalescent-phase serum specimens were obtained within 60 days of illness onset.


Sixty suspected cases of psittacosis were identified among workers at plant A. Of these, 40 (67%) met the definition for a confirmed case (Figure 1). Thirty-nine cases were confirmed by serology alone; one also was confirmed by isolation of *Chlamy-dia* from a bronchial washing specimen. Records were available for 38 patients; among these patients, the most frequently recorded symptoms were fever (89%) and cough (71%). Other reported symptoms included aches (42%), chest pain (39%), headache (37%), nausea (37%), vomiting (34%), diarrhea (34%), and abdominal pain (18%). Twenty-four (60%) of the 40 persons meeting the case definition were hospitalized.

For the 32 patients with confirmed psittacosis whose temperatures were recorded, the mean maximum body temperature was 39.4 C (103 F) (range: 36.6–41.1 C [98–106 F]; median: 39.4 C [103 F]). The mean maximum white blood cell (WBC) count for the 22 patients whose WBC counts were recorded was 10,600 per mm<sup>3</sup> (range: 7100–20,900 per mm<sup>3</sup>; median: 10,100 per mm<sup>3</sup>). Abnormal chest radiograph results were reported for at least 29 patients, and abnormal liver function tests, for at least seven.

Thirty-eight (95%) of those meeting the case definition worked on the day shift at plant A. Day-shift employees working in the "chilling," "cut-up/debone," and "other" areas of the plant had direct contact only with cleaned and processed turkeys and (Continued on page 467)

FIGURE 1. Confirmed psittacosis cases in plant A employees, by date of onset – North Carolina, October 1989





# FIGURE I. Notifiable disease reports, comparison of 4-week totals ending July 7, 1990, with historical data – United States

\*Ratio of current 4-week total to mean of 15 4-week totals (from comparable, previous, and subsequent 4-week periods for past 5 years).

#### TABLE I. Summary – cases of specified notifiable diseases, United States, cumulative, week ending July 7, 1990 (27th Week)

	Cum. 1990		Cum. 1990
AIDS Anthrax Botulism: Foodborne Infant Other Brucellosis Cholera Congenital rubella syndrome Diphtheria Encephalitis, post-infectious Gonorrhea: civilian military Leprosy Leptospirosis Measles: imported indigenous	22,246 1 26 2 33 1 1 1 50 337,136 4,675 98 23 745 13,577	Plague Poliomyelitis, Paralytic* Psittacosis Rabies, human Syphilis: civilian military Syphilis, congenital, age < 1 year Tetanus Toxic shock syndrome Trichinosis Tuberculosis Tuberculosis Tularemia Typholi fever Typhus fever, tickborne (RMSF)	- 70 1 24,762 131 - 26 173 15 10,878 44 196 185

\*Three cases of suspected poliomyelitis have been reported in 1990; five of the 13 suspected cases in 1989 were confirmed and all were vaccine-associated.

		Aseptic	Encep	halitis	0	rehoc	н	epatitis (	Viral), by	type		
Reporting Area	AIDS	Menin- gitis	Primary	Post-in- fectious		rrhea ilian)	Α	В	NA,NB	Unspeci- fied	Legionel- losis	Leprosy
	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1989	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1990
UNITED STATES	22,246	2,831	334	50	337,136	343,601	14,960	10,390	1,035	899	551	98
NEW ENGLAND	800	113	10	-	9,227	9,666	295	541	34	39	26	5
Maine N.H.	36 43	4 10	1	-	108 104	141 87	5 5	24 24	4 3	1	2 3	-
Vt.	43	12	2	-	33	36	5	24 29	3	2	35	-
Mass.	439	35	2	-	3,679	3,787	219	341	16	35	11	4
R.I. Conn.	43 232	38 14	1 4	-	543 4,760	683 4,932	28 35	27 96	- 8	1	5	1
MID. ATLANTIC	7,100	300	31	4	46,340	52,570	2,157	1,524	121	66	160	17
Upstate N.Y. N.Y. City	1,083 3,978	137	26	1	7,036	7,916	519	360	28	19	70	1
N.J.	3,978	67	2 1	1	19,624 7,234	21,347 7,163	269 227	448 345	18 28	31	25 25	12 3
Pa.	675	96	2	2	12,446	16,144	1,142	371	47	16	40	1
E.N. CENTRAL Ohio	1,576	413	73	8	64,595	59,386	1,069	1,284	71	55	127	1
Ind.	373 137	91 80	18 2	3 3	19,889 5,696	15,637 4,631	120 70	231 256	22 4	8 14	47 22	-
Ш.	675	72	22	2	20,303	18,131	498	222	22	15	8	1
Mich. Wis.	271 120	147 23	29 2		15,071 3,636	15,811 5,176	198 183	360 215	19 4	18	36 14	-
W.N. CENTRAL	511	111	32	1	17,877	15,732	851	501	68	17	32	
Minn.	83	9	11	i	2,206	1,611	135	58	18	-	-	-
lowa	25	13	4		1,341	1,317	175	36	5	2	2	-
Mo. N. Dak.	305 1	51 6	3		10,672 55	9,327 71	285 9	314 4	25 2	11 1	19	
S. Dak.	1	4	2		109	139	64	4	2	-	-	-
Nebr. Kans.	24 72	11 17	4 8	-	857 2,637	873 2,394	49 134	22 63	4 12	- 3	6 5	-
S. ATLANTIC	4,745	654	76	14	96,290	94,194	1,811	1,969	166	136	77	4
Del.	51	22	3	-	1,621	1,522	73	54	6	2	5	-
Md. D.C.	483	77	10	1	10,433	10,305	679	271	19 4	6	22	2
Va.	326 439	2 92	25	2	6,712 8,234	6,204 7,811	12 156	28 118	4 25	97	7	:
W. Va.	35	15	6	-	653	691	11	49	3	1	1	
N.C. S.C.	309	70	23	-	15,511	13,872	363	551 320	69 11	-7	13 12	1
Ga.	178 646	10 109	1 3	1	7,662 21,537	8,564 18,106	23 188	239	4	, 7	12	
Fla.	2,278	257	5	10	23,927	27,119	306	339	25	16	5	1
E.S. CENTRAL	522	282	27	1	27,070	27,157	207	805	67	5	41 18	-
Ky. Tenn.	95 172	65 48	7 14	- 1	3,010 8,492	2,591 8,860	52 99	275 429	21 30	4	18	-
Ala.	121	118	6		8,715	8,654	55	97	14	-	11	-
Miss.	134	51	-	-	6,853	7,052	1	4	2	1	-	-
W.S. CENTRAL Ark	2,245 85	288 5	13	6	34,832	35,913	1,495 267	916 46	45 5	144 12	31 7	23
La.	382	46	1 4	-	4,502 7,102	3,672 7,364	93	159	2	4	10	
Okla. Tex.	120	22	1	5	3,117	3,046	305	76	15	13	10	-
MOUNTAIN	1,658	215	7	1	20,111	21,831	830	635 785	23 81	115 72	4 25	23
Mont.	560 7	131 2	12	:	6,636 97	7,385 104	2,405 63	39	2	4	25	-
Idaho	14	-		-	62	101	44	49	8	-	3	-
Wyo. Colo.	2 161	1	1	:	92	50 1,635	23 148	9 86	5 25	1 24	- 3	-
N. Mex.	51	27 6	3	-	1,323 644	727	393	90	25	24	3	
Ariz. Utah	190	62	4	-	2,808	2,727	1,339	276	21	29	8	-
Nev.	51 84	19 14	4	-	220 1,390	226 1,815	203 192	52 184	11 4	3 9	2 5	-
PACIFIC	4,187	539		16	34,269	41,598	4,670	2,065	382	365	32	48
Wash.	326	-	3	1	2,834	3,256	798	327	72	15	8	3
Oreg. Calif.	164	-	-	-	1,316	1,539	473	230 1,437	21 277	6 339	23	- 37
Alaska	3,602 20	481 15	52 4	14	29,322 534	36,085 460	3,245 98	1,437	3	-	-	-
Hawaii	75	43	1	1	263	258	56	35	9	5	1	8
Guam P.R.	1	-		-	100	76	5	1	2	7	-	
V.I.	877 4	37	6	-	455 233	594 353	95 1	164 8	2	22		-
Amer. Samoa C.N.M.I.	*	1	-	-	43	12	18	-	-	-	-	9
0.04.1VI.1.	-	-	-	-	101	51	8	6	-	15	•	2

# TABLE II. Cases of specified notifiable diseases, United States, weeks endingJuly 7, 1990, and July 8, 1989 (27th Week)

N: Not notifiable

	Malaria	India	Meas	es (Rub		<b>.</b>	Menin- gococcal	Mu	mps		Pertussi	s	Rubella		
Reporting Area	Cum. 1990	1990	Cum. 1990	Impo 1990	Cum. 1990	Total Cum. 1989	Infections Cum. 1990	1990	Cum.	1990	Cum.	Cum.	1990	Cum.	Cum
UNITED STATES	550	392	13,577	17	745				1990		1990	1989		1990	1989
NEW ENGLAND	51	332	13,577			8,663	1,483	75	3,249	38	1,508	1,282	11	619	236
Maine	1	-	27	2	20 2	296	109 10	:	31	2	194 6	225 4	2	7	6
N.H.	4	-	-	-	8	8	3	-	7		12	4 5		1	4
Vt. Mass.	4 30	-	15	-	1	2	10	-	1	-	6	6	-		1
R.I.	4	-	15 27	2†	4 3	41 41	55 10	-	8 5	2	158 2	193 8	2	2 1	1
Conn.	8	-	105	-	2	204	21		10	:	10	9		3	-
MID. ATLANTIC	117	21	779	7	144	803	219	4	194	2	306	85		2	17
Upstate N.Y.	22	5	194	5†§	107	134	86	3	85	1	244	35	-	1	5
N.Y. City N.J.	41 39	10	142	-	19	63	25	-	-	-	-	2	-	-	10
Pa.	15	6	105 338	- 2§	9 9	401 205	48 60	- 1	40 69	1	13 49	23 25	•	1	2
E.N. CENTRAL	25	3	2,802										•		
Ohio	25	-	2,802	-	141 3	2,277 661	196 64	-	340	5	299	154	-	29	23 3
Ind.	1	-	312	-	1	51	19		75 13	3	86 56	1 13		1	-
III. Mich.	9 7	-	1,022	-	10	1,399	47	-	105	-	81	68	-	17	18
Wis.	3	3	328 689	-	125 2	15	45	•	111	2	38	24	-	9	1
W.N. CENTRAL				-		151	21	-	36	-	38	48	-	2	1
Minn.	8 1	36 36	682 275	-	13 3	539 7	50 10	-	87	1	52	54	-	6	4
lowa	i	-	275	-	1	5	10	-	14	-	6 6	7 10		1	
Mo.	5	-	66	-	-	307	19	-	41	1	33	33	-	-	3
N. Dak. S. Dak.	-	-	- 15	-	-	-	-	-	-	-	1	-	-	1	-
Nebr.	-	-	97	-	8 1	112	2		3	-	1	1 2	-	-	-
Kans.	1	-	206	-		108	13		29	-	2 3	1	-	-	1
S. ATLANTIC	125	11	762	2	114	391	271	54	1,359	4	137	90		13	8
Del.	2	-	8	-	3	37	1	-	1,359	4	2	90 1	-	-	-
Md. D.C.	31	9	181	-	18	50	30	27	804	1	37	10	-	1	2
Va.	10 33	-	10 66	:	7 2	12 20	11 35	-	24	-	14	-	-	1	
W. Va.	1	-	6	-	-	28	12	-	77 41	1	14 10	6 12	-	-	-
N.C.	8	1	10	2†§	13	167	41	21	185	i	32	20	-	-	1
S.C. Ga.	11	-	4 61	:	- 16	-	20	-	21	-	5		-	-	-
Fla.	29	1	416	-	55	77	50 71	6	56 148	-	14 9	10 31	-	10	5
E.S. CENTRAL	12	8	110		2										2
Ky.	2	-	24			109 10	86 27	2	64	3	81	52 1		1	-
Tenn.	6	8	42	-	-	55	32	2	32	1	29	15	-	1	2
Ala. Miss.	4	-	15 29		2	44	25	-	9	2	47	30	-	-	-
W.S. CENTRAL					•	-	2	Ν	N	-	5	6	-	-	-
Ark.	26 1	302	3,647 10	5	85	2,812	101	7	525	4	37	75	-	2	22
La.	i	-	10	•	28	2	14 26	2	128 86	- 1	2 11	11 5	-	1	5
Okla.	7	4	152	-	-	92	11	3	103	3	24	5 14	-	1	1
Tex.	17	298	3,475	5†	57	2,712	50	2	208		-	45		-	16
MOUNTAIN	15	11	637	1	83	271	48	5	264	2	157	386	3	96	35
Mont. Idaho	1 3	-	-	-	1	13	9	-	-	-	23	10	-	13	1 32
Wyo.	-	-	15	:	6 11	2	5	2	134	1	32	53	-	46	32
Colo.	2	6	76	1§	39	61	14	1	2 19	-	52	23	-	3	-
N. Mex. Ariz.	1	1	82	-	11	31	8	Ň	N	1	9	6	-	-	-
Utah	7	3 1	235 56		12	72	4	1	87	-	27	285	3	29 1	
Nev.	1		173		3	90 2	4	1	8 14	-	10 4	8 1	2	4	1
PACIFIC	171	-	3,984		143	1,165		•					<u>^</u>	463	119
Wash.	16	-	176	-	68	33	403 49	3	385 38	15 5	245 63	161 48	6	403	-
Oreg.	10	-	138	-	44	13	45	N	38 N	5	7	40	-	5	2
Calif. Alaska	140 2	-	3,586	-	28	1,099	298	3	338	9	155	103	5	449	96
Hawaii	2	-	78 6		2 1	23	7	-	-	1	1		-	- 9	21
Guam			0				4	-	9	-	19	4	1	3	- '
P.R.	1	U	808	U	1	1 437	-	U	1	U	2	1	U	-	6
V.I.	-	-	21	-	3	437	9	1	7 6	-	5	3	:		-
Amer. Samoa	-	U	89	U	-	-	-	ΰ	9	Ū	-	-	U		-
C.N.M.I.	-	U	-	U	-	-	-	Ŭ	7	ŭ	-	-	Ũ		-

# TABLE II. (Cont'd.) Cases of specified notifiable diseases, United States, weeks endingJuly 7, 1990, and July 8, 1989 (27th Week)

\*For measles only, imported cases includes both out-of-state and international importations. N: Not notifiable U: Unavailable <sup>†</sup>International <sup>§</sup>Out-of-state

Reporting Area	Syphilis (Primary &	(Civilian) Secondary)	Toxic- shock Syndrome	Tubero	culosis	Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabies, Anima
	Cum. 1990	Cum. 1989	Cum. 1990	Cum. 1990	Cum. 1989	Cum. 1990	Cum. 1990	Cum. 1990	Cum. 1990
UNITED STATES	24,762	21,608	173	10,878	10,637	44	196	185	2,087
NEW ENGLAND	926	852	12	248	273	1	13	4	4
Maine N.H.	5	5	3		3		-	-	-
Vt.	39 1	6	1	3 7	16 4		-	-	2
Mass.	353	261	7	130	142	1	12	3	
R.I. Conn.	7	15		35	33	•	-	-	-
	521	565	1	73	75	•	1	1	2
MID. ATLANTIC Upstate N.Y.	5,410	4,516	17	2,698	2,048	1	50	8	469
N.Y. City	426 2,397	456 1,967	6 5	235 1,603	177 1,159	-	9 27	4	23
N.J.	856	684	-	466	339	1	12	3	141
Pa.	1,731	1,409	6	394	373	-	2	1	305
E.N. CENTRAL	1,703	865	44	1,132	1,127		19	16	61
Ohio	273	67	16	172	216	-	4	11	3
Ind. III.	34	33	2	94	108	-	1	-	-
Mich.	648 569	375 329	5 21	565 252	493 248		10 3	- 5	17 9
Wis.	179	61	-	49	62		1	-	32
W.N. CENTRAL	222	175	23	284	272	16	-	16	343
Minn.	49	16	1	53	53	-	-	-	121
lowa	30	21	4	33	28	-	-		17
Mo. N. Dak.	117 1	91	11	134	119	14	-	13	13
S. Dak.	1	2	-	10 9	11 14	1	-	-	46 113
Nebr.	8	17	3	13	10	i	-	-	4
Kans.	16	28	4	32	37	•	-	3	29
S. ATLANTIC	7,857	7,830	15	2,258	2,214	3	22	75	596
Del. Md.	99	85	1	23	25		-	1	8
D.C.	591 506	388 469	1 1	179 80	184 89	-	8	5	222
Va.	392	271		159	196	1	2	2	105
W. Va.	7	9	-	38	40	-	-	-	19
N.C. S.C.	912 483	479	10	262	260	1	2	44	4 77
Ga.	2,048	390 1,864	1	262 453	248 345		1	20 3	115
Fla.	2,819	3,875	1	802	827	-	9		46
E.S. CENTRAL	2,164	1,353	6	849	909	5	1	23	104
Ky.	39	32	ĭ	206	214	1	1	3	26
Tenn. Ala.	871	588	3	234	262	4	-	16	27
Miss.	663 591	421 312	2	264 145	253 180		-	4	51
W.S. CENTRAL						40	-	20	050
Ark.	3,803 260	2,850 168	7	1,361 157	1,239 131	13 8	5	36 5	253 22
La.	1,065	662	1	140	137		-	1	
Okla. Tex,	116	46	6	106	109	5	2	27	75
	2,362	1,974	-	958	862	-	3	3	156
MOUNTAIN Mont.	460	366	20	245	239	4	17	5	99
Idaho	6	1	- 1	10 8	7 8		-	3	29 1
Wyo.	-	3	2	3	-	1	-	-	31
Colo. N. Mex.	22	52	6	14	20	-	-	-	3
Ariz.	24 332	17 118	4 5	52	43 112	3	- 15	1	6 24
Utah	332	118	5	120 12	24		15	-	24
Nev.	72	163	-	26	25	-	2		2
PACIFIC	2,217	2,801	29	1,803	2,316	1	69	2	158
Wash. Oreg.	191	225	4	135	114	1	2	-	-
Calif.	76	137		61	74	•	2	-	-
Alaska	1,932 10	2,430 2	24	1,505 21	2,009 35	-	62	2	136 22
Hawaii	8	7	1	81	84		3		
Guam	1	4		14	40		_	-	-
P.R. V.I.	197	290	-	66	151		-	-	27
V.I. Amer. Samoa	1	2	-	4	4		-	-	-
C.N.M.I.	-	-	-	8	2		1	-	
	1	7	-	23	9	•	4	-	-

# TABLE II. (Cont'd.) Cases of specified notifiable diseases, United States, weeks endingJuly 7, 1990, and July 8, 1989 (27th Week)

U: Unavailable

#### All Causes, By Age (Years) All Causes, By Age (Years) P&I\*\* P&I\*\* **Reporting Area Reporting Area** All ΔII Total ≥65 45-64 25-44 1-24 <1 Total 1-24 <1 ≥65 45-64 25-44 Ages Ages NEW ENGLAND S. ATLANTIC 1.031 Boston Mass Atlanta, Ga. Bridgeport, Conn. Baltimore, Md. ŝ Cambridge, Mass. Charlotte, N.C. Fall River, Mass. ŝ Jacksonville, Fla. Hartford, Conn. Miami, Fla. Lowell, Mass. . Norfolk, Va Lynn, Mass. Ā Richmond, Va. New Bedford, Mass. Savannah, Ga. New Haven, Conn. St. Petersburg, Fla. Providence, R.I. Tampa, Fla. Somerville, Mass. . Washington, D.C. Springfield, Mass. Wilmington, Del. Waterbury, Conn. E.S. CENTRAL Worcester, Mass. Birmingham, Ala. 2,436 MID ATLANTIC 1.599 ž Chattanooga, Tenn. Albany, N.Y. Knoxville, Tenn. Allentown, Pa. ğ Louisville, Ky. Buffalo, N.Y 5 Memphis, Tenn. Camden, N.J. Mobile, Ala. Elizabeth, N.J. Montgomery, Ala. Λ Erie, Pa.† Nashville, Tenn. Jersey City, N.J. N.Y. City, N.Y. W.S. CENTRAL 1.601 1,287 Newark, N.J. Austin, Tex. Baton Rouge, La Paterson, N.J. ž Philadelphia, Pa.§ Corpus Christi, Tex. Pittsburgh, Pa.t Dallas, Tex. з Reading, Pa. El Paso, Tex. Fort Worth, Tex Rochester, N.Y Schenectady, N.Y. Houston, Tex.§ Scranton, Pa.† Little Rock, Ark. New Orleans, La Svracuse, N.Y. Trenton, N.J. San Antonio, Tex. Utica, N.Y. Shreveport, La. Tulsa, Okla. Yonkers, N.Y. à E.N. CENTRAL 2.030 MOUNTAIN 1,343 Akron, Ohio ż Albuquerque, N. Mex. Colo. Springs, Colo. Canton, Ohio Chicago, III.§ Denver, Colo. Ŕ Las Vegas, Nev. Cincinnati, Ohio Ogden, Utah Cleveland, Ohio Columbus, Ohio Phoenix, Ariz. Dayton, Ohio Pueblo, Colo. Detroit, Mich. Salt Lake City, Utah 12 Evansville, Ind. Tucson, Ariz. Fort Wayne, Ind. 17 PACIFIC 1,718 1,129 Gary Ind Berkeley, Calif. Grand Rapids, Mich. Δ Fresno, Calif. 1ō Indianapolis, Ind. Glendale, Calif. Madison, Wis Honolulu, Hawaii Milwaukee, Wis. Long Beach, Calif. Peoria, III. Los Angeles Calif. Rockford, III. ĩ Oakland, Calif. South Bend, Ind. Pasadena, Calif. Toledo, Ohio Portland, Oreg. Youngstown, Ohio ã Sacramento, Calif. W.N. CENTRAL San Diego, Calif. Des Moines, Iowa San Francisco, Calif. ĝ Duluth, Minn. San Jose, Calif. Kansas City, Kans. Seattle, Wash. Kansas City, Mo. Spokane, Wash. Tacoma, Wash. Lincoln, Nebr. Minneapolis, Minn. 11,409 \*\* 7,391 2,261 1,076 TOTAL Omaha, Nebr. 7 St. Louis, Mo. St. Paul, Minn. Wichita, Kans.

TABLE III. Deaths in 121 U.S. cities,\* week ending July 7, 1990 (27th Week)

\*Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

\*\*Pneumonia and influenza.

tBecause of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

††Total includes unknown ages.

\$Data not available. Figures are estimates based on average of past available 4 weeks.

# Psittacosis – Continued

appeared to be at lowest risk for meeting the case definition (Table 1). In contrast, workers exposed to turkey viscera in the "offal/truckwash," "U.S. Department of Agriculture (USDA) inspection," and "evisceration" areas were at highest risk. Workers exposed to live birds and their feces in the "live hang" area (where live turkeys are uncrated and hung on the processing line) were at intermediate risk (Table 1).

A plant veterinarian reported that a portion of a flock of tom turkeys processed at plant A during the day shift on September 29 had a carcass condemnation rate of 25% attributed to air sacculitis\*; the usual rate of carcass condemnation at plant A is 1%–3%. None of the condemned carcasses or specimens from that flock were retained for necropsy, culture, or further examination. Assuming that exposure occurred on September 29, the mean incubation period for the 40 cases was 15 days (range: 3–31 days; median: 14 days) (Figure 1).

The total compensation disability insurance payments to 34 psittacosis patients was nearly \$13,000, and the total medical costs paid for 35 patients was >\$124,000, according to information from plant A's workers' compensation insurer.

Reported by: JA Rhyne, MD, Wilmington; L Hunter, DVM, C Staes, MPH, RA Meriwether, MD, JN MacCormack, MD, State Epidemiologist, North Carolina Dept of Environment, Health, and Natural Resources. Div of Field Svcs, Epidemiology Program Office, CDC.

**Editorial Note:** Psittacosis ("parrot fever") is caused by the obligate intracellular bacterium *C. psittaci*, which can infect a variety of mammalian, avian, and reptilian species (1). Inhalation of infectious aerosols derived from feces, fecal dust, and secretions of *C. psittaci*-infected animals is believed to be the primary route of infection for most psittacosis patients; percutaneous exposure may be an alternate, but less important, route (1-3). Most cases of psittacosis are attributed to exposure to infected birds. The source birds can be asymptomatically infected (i.e., carriers) or can show signs of infection, such as anorexia, ruffled feathers, depression, and watery, green droppings.

Work area	No. employees	No. cases	(%)	Relative risk*	95% Cl <sup>↑</sup>
Offal/truckwash	3	1	(33)	48.3	6.8–342.4
U.S. Department of Agriculture inspection	6	2	(33)	48.3	9.8–238.8
Evisceration	138	30	(22)	31.5	9.8–101.7
Live hang	26	2	(8)	11.2	2.063.9
Chilling	67	1	(1)	1.0	
Cut-up/debone	187	2	(1)	1.0	
Other	181	0		1.0	
Total	608	38	(6)		

 TABLE 1. Confirmed cases of psittacosis among day-shift employees at plant A, by

 work area
 North Carolina, October 1989

\*The "chilling," "cut-up/debone," and "other" turkey handling departments were the reference group for comparison.

<sup>†</sup>Confidence interval.

<sup>\*</sup>An avian disorder similar to pleurisy in mammals that is a common but nonspecific manifestation of psittacosis in turkeys.

### Psittacosis – Continued

Psittacosis is a rarely reported mild illness with no specific signs and symptoms, most often occurring as a sporadic illness in persons having contact with infected cage birds. Occasionally, clusters of cases occur among workers at poultry processing plants or in other settings (1,2). The diagnosis can be established with certainty only by paired serologic testing or identification of the organism by culture. In North Carolina, the nation's largest turkey-producing state (>50 million turkeys produced each year), fewer than 10 cases of psittacosis per year have been reported in the past 10 years; most cases were related to pet bird exposure.

The clinical and epidemiologic findings of the North Carolina study are comparable to those in other reported outbreaks (1,3). This report demonstrates that poultry workers having contact with turkey viscera and feces or with live birds are at greatest risk for psittacosis. However, it also supports a recent report from Minnesota (3) in which defeathered, eviscerated, and chilled turkey carcasses may transmit psittacosis. In addition, in both of these outbreaks, the incubation period for psittacosis was longer than the 4–14 days commonly cited (1,2).

The principal strategies for the elimination of psittacosis outbreaks among poultry workers are reducing *C. psittaci* infection in the flocks and protecting workers from exposure to the organism, even if they work with infected birds. Raising turkey flocks in controlled, indoor environments would minimize the contact between domesticated fowl and *C. psittaci*-infected wild birds and animals, thereby reducing the risk for infection in the flocks. Testing of flocks for *C. psittaci* infection is difficult, time consuming, and nonspecific because the majority of strains isolated have no potential for causing human illness. Testing ill birds in flocks for *C. psittaci* infection and treating infected flocks with chlortetracycline according to USDA regulations before slaughter may reduce worker exposure to this agent. Nevertheless, birds can remain asymptomatically infected after treatment (4) and can transmit infection at slaughter to humans.

As a result of the North Carolina outbreak, the management of plant A initiated an ongoing program of increased flock surveillance for ill turkeys. A short-term program of culturing flocks raised on open land for *Chlamydia* species and necropsy of any dead birds was also initiated. When chlamydial infection was detected, the implicated flocks were treated with chlortetracycline according to USDA regulations, and plant A employees were strongly encouraged to wear paper face masks when these flocks were processed.

The use of respiratory protection approved by the Mine Safety and Health Administration and by CDC's National Institute for Occupational Safety and Health (NIOSH) may further reduce the inhalation risk of exposure to infectious *Chlamydia* aerosols (5,6). However, no research-based information exists on which to recommend an appropriate class of respirator.

#### References

- CDC. Psittacosis surveillance, 1975–1984. Atlanta: US Department of Health and Human Services, Public Health Service, 1987.
- Schaffner W. Psittacosis. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. New York: John Wiley and Sons, 1979:1476–9.
- Hedberg K, White KE, Forfany JC, et al. An outbreak of psittacosis in Minnesota turkey industry workers: implications for modes of transmission and control. Am J Epidemiol 1989;130:569–77.
- Benenson AS, ed. Control of communicable diseases in man. 13th ed. Washington, DC: American Public Health Association, 1980.

#### Vol. 39 / No. 27

#### Psittacosis - Continued

- Office of the Federal Register. Code of federal regulations: occupational safety and health standards. Subpart I. Personal protective equipment. Washington, DC: Office of the Federal Register, National Archives and Records Administration, 1983. (29 CFR § 1910.134).
- NIOSH. Guide to industrial respiratory protection. Cincinnati, Ohio: US Department of Health and Human Services, Public Health Service, CDC, 1987; DHHS publication no. (NIOSH)87-116.

## Notices to Readers

# Clarification: Vol. 39, No. RR-7

After publication of the MMWR Recommendations and Reports entitled Prevention and Control of Influenza: Recommendations of the Immunization Practices Advisory Committee (ACIP) (1), Table 1 was modified to clarify that, as in previous years, only split-virus vaccines should be given to children  $\leq$ 12 years of age. The change from previous ACIP recommendations is that children 9–12 years of age may receive one dose of vaccine rather than the previously recommended two doses.

#### Reference

1. ACIP. Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990;39(no. RR-7):4.

Age group	Product <sup>†</sup>	Dosage	No. doses	Route <sup>s</sup>
6–35 mos.	Split virus only	0.25 mL	1 or 2*	IM
3–8 yrs.	Split virus only	0.50 mL	1 or 2 <b>°</b>	IM
9–12 yrs.	Split virus only	0.50 mL	1	IM
>12 yrs.	Whole or split virus	0.50 mL	1	IM

### TABLE 1. Influenza vaccine\* dosage, by patient age — United States, 1990–91 season

\*Contains 15 µg each of A/Taiwan/1/86-like (H1N1), A/Shanghai/16/89(H3N2), and B/Yamagata/ 16/88-like hemagglutinin antigens in each 0.5 mL. Manufacturers include: Connaught Laboratories, Inc. (distributed by E.R. Squibb & Sons, Inc.) (Fluzone® whole or split); Evans Medical Ltd.-Lederle Laboratories (distributed by Lederle Laboratories) (Flu-Imune® purified surface antigen vaccine); Parke-Davis (Fluogen® split); and Wyeth-Ayerst Laboratories (Influenza Virus Vaccine, Trivalent® split). For further product information call Connaught, (800) 822-2463; Lederle, (800) 533-3753; Parke-Davis, (800) 223-0432; Wyeth-Ayerst, (800) 950-5099.

<sup>†</sup>Because of the lower potential for causing febrile reactions, only split-virus vaccines should be used in children. They may be labeled as "split," "subvirion," or "purified-surface-antigen" vaccine. Immunogenicity and side effects of split- and whole-virus vaccines are similar in adults when vaccines are used at the recommended dosage.

<sup>§</sup>The recommended site of vaccination is the deltoid muscle for adults and older children. The preferred site for infants and young children is the anterolateral aspect of the thigh.

Two doses are recommended for children <9 years of age who are receiving influenza vaccine for the first time.

## **Rabies and Rickettsial Diseases Hotline**

CDC's Viral and Rickettsial Zoonoses Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, now has a 24-hour-a-day automated telephone system that provides information to the public on rabies, Rocky Mountain spotted fever, and human ehrlichiosis. Menu options include information on animal and tick bites, requests for written information, rabies prevention recommendations for international travelers, and the procedure for reporting rabies vaccine reactions. To access this information, call the CDC Information Hotline at (404) 332-4555.

,

The Morbidity and Mortality Weekly Report is prepared by the Centers for Disease Control, Atlanta, Georgia, and available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, (202) 783-3238.

The data in this report are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday. The editor welcomes accounts of interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Such reports and any other matters pertaining to editorial or other textual considerations should be addressed to: Editor, *Morbidity and Mortality Weekly Report*, Centers for Disease Control, Atlanta, Georgia 30333; telephone (404) 332-4555.

Director, Centers for Disease Control William L. Roper, M.D., M.P.H. Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.

Editor, *MMWR* Series Richard A. Goodman, M.D., M.P.H. Managing Editor Karen L. Foster, M.A.

☆U.S. Government Printing Office: 1990-731-103/22009 Region IV

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Centers for Disease Control Atlanta, GA 30333

FIRST-CLASS MAIL POSTAGE & FEES PAID PHS/CDC Permit No. G-284

Official Business Penalty for Private Use \$300

> Z4 \*HCRU9FISD22 8721 DANIEL B FISHBEIN, MD CID, VRL 7-844 G13

х